Spotlight on Trastuzumab as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

被引：4
|
作者：
Garnock-Jones, Karly P. [1 ]
Keating, Gillian M. [1 ]
Scott, Lesley J. [1 ]
机构：
[1] Adis, Auckland, New Zealand
来源：
BIODRUGS | 2010年 / 24卷 / 03期
关键词：
COMPLEX-FORMATION; HERCEPTIN; CHEMOTHERAPY; DOXORUBICIN; INHIBITION; MODULATION; PACLITAXEL; MECHANISM; ANTIBODY; SUBTYPES;
D O I：
10.2165/11204680-000000000-00000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：207 / 209
页数：3
相关论文
共 50 条
  • [31] Left heart remodelling one year after adjuvant treatment with trastuzumab in women with positive human epidermal growth factor type 2 receptor (HER-2) breast cancer
    Piotrowski, G.
    Bodnar, L.
    Gawor, R.
    Strzelecki, P.
    Majzner, M.
    Timler, D.
    Potemski, P.
    Gawor, Z.
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 12 : S209 - S210
  • [32] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [33] Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
    Ricardo H. Alvarez
    Gabriel N. Hortobagyi
    Breast Cancer, 2013, 20 : 103 - 110
  • [34] Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
    Alvarez, Ricardo H.
    Hortobagyi, Gabriel N.
    BREAST CANCER, 2013, 20 (02) : 103 - 110
  • [35] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
    Baselga, Jose
    Perez, Edith A.
    Pienkowski, Tadeusz
    Bell, Richard
    ONCOLOGIST, 2006, 11 : 4 - 12
  • [36] De-Escalating Treatment Strategies for Patients with Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Early-Stage Breast Cancer
    Abdel-Razeq, Hikmat
    CANCERS, 2024, 16 (20)
  • [37] Real-world treatment patterns in patients with human epidermal growth factor receptor 2 (HER2) - positive early breast cancer in Serbia and Montenegro - HEReNA
    Spasojevic, I. Bozovic
    Kovacevic, M. Milovic
    Lekic, S.
    Cvetanovic, A.
    Bjelobrk, I. Kolarov
    Lucic, J.
    Andric, Z.
    Milenkovic, D.
    Saric, N. Cicmil
    Vukovic, I.
    Petronijevic, M.
    Calamac, M.
    Djurmez, O.
    Djuric, S.
    Perduv, V.
    Radisavljevic, M.
    Popovic, L.
    BREAST, 2025, 80
  • [38] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [39] A human epidermal growth factor receptor 3 (HER3)-binding nanoparticle targets and kills Herceptin®-resistant human epidermal growth factor receptor 2 (HER2)-positive breast cancer
    Sims, J. D.
    Taguaim, M.
    Hanson, C.
    Cui, X.
    Medina-Kauwe, L. K.
    CANCER RESEARCH, 2013, 73
  • [40] Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
    Riecke, Kerstin
    Witzel, Isabell
    BREAST CARE, 2020, 15 (06) : 579 - 585
12345